Former Netflix CFO David Wells bought $1.2M of HIMS stock at $24.23 on May 26, marking his first open-market purchase in nearly 5 years, despite the C-suite selling heavily and Q1 missing on earnings. The purchase suggests confidence in the company's GLP-1 transition, Wegovy ramp (125K shipments in 6 weeks), and international expansion (969% YoY growth), though near-term execution risk remains given the stock's current depressed valuation.

Author is bullish on $HIMS based on technical chart patterns showing a bounce off the 200-day moving average and potential golden cross, combined with the company's direct-to-consumer telehealth model for prescription medications. Key risks include the speculative nature of the trade, reliance on technical analysis alone, and the competitive telemedicine market.